HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
about
Update and new approaches in the treatment of Castleman diseaseCo-infections and Pathogenesis of KSHV-Associated MalignanciesEmerging treatments in Castleman disease - a critical appraisal of siltuximabTaking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease ResearchReview of siltuximab in the treatment of multicentric Castleman's diseaseTAFRO syndrome: 2 cases and review of the literature.Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review.Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.A case of TAFRO syndrome with a large mediastinal mass treated with debulking surgeryAn anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and tocilizumab therapy.Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman diseaseTAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature.International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America.Anasarca, Fever, Thrombocytopenia, Organomegaly, and Multiorgan Failure in a 24-Year-Old Pregnant Woman.CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman diseaseThoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions.Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.Multicentric Castleman's disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report.Unicentric Castleman's disease presenting as a pulmonary mass: a diagnostic dilemmaCastleman Disease. A Report of Six Cases.Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease: renal function is an important prognostic factorEnhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related diseaseSiltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.Autoimmune and Lymphoproliferative Complications of Common Variable Immunodeficiency.Multicentric Castleman disease: Where are we now?JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease.Clinical spectrum of Castleman disease-associated neuropathy.Lung Disease in Primary Antibody Deficiencies.Siltuximab for multicentric Castleman disease.Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder.Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.Castleman disease and lymphocytic interstitial pneumonia: a complex diagnostic and management challenge.
P2860
Q26740703-2FBA40CC-BF2C-4B1A-BF00-31BB3D359662Q26766493-13F7CE19-2AF7-41CB-B298-877F748E674EQ26766554-FBC66422-1975-48F5-84AC-105DE1A9C9E3Q26775808-E5F5B20D-7AB9-468A-9FCD-FFB855AFAAE9Q28067246-30072CB4-50D8-4543-8728-1831467BEB0CQ33423479-82712E3C-B1CE-48BF-AADE-5664A4A22391Q33429461-E221D7A4-400D-4803-B12E-8A8866AD34DAQ33430083-93FAD180-78F8-4F75-819C-B550D480EBA3Q33430748-85934F54-CBEE-45E6-9D84-BE24E6C52265Q33431547-673CBEE8-D43F-4C28-B981-ED2FDDC9D247Q33433216-E65166B6-DC16-425E-83D2-6EF122EDB67DQ33434530-9ADBFE63-790F-426D-B67F-EE34F7121F9EQ33436014-BEA0F50F-1600-487F-8B81-59FE4A44958CQ33436275-AAEB6D2D-1457-4BFF-83D8-F8045C0BD355Q33438403-1CB82398-8844-4BAA-846F-2476D2F6464BQ33438812-D4BDC5DF-C2C6-44E0-BF11-0A7AE55C7A64Q33439399-DEA30F60-8BC5-4A65-8D4B-84A592ECEF9FQ33440516-7D49E28C-801D-4245-95E4-CD1FCE3F8711Q33443714-B3BC972B-04F0-41E3-BB51-616E8F67035EQ34460823-2281AB5C-EE20-47A5-802C-FF6635098DE2Q34636851-4B84428F-D156-4458-BEE7-76686B24434AQ34716216-6401405C-4C50-42C5-93C4-0C36D103CE6AQ35252771-930FAAFE-226F-4752-8359-C1B6CA45B4F2Q35554559-72D2843B-2DF6-445C-8852-E79FBDA42112Q35579267-757094C4-C36E-4DAF-9073-1EACB6555AA3Q35869087-146C3DDA-7066-487A-959F-C54377DFB40CQ36748340-2DF3A54E-01FD-4CD0-BACE-7C224BBA953EQ37093426-DF811620-4311-4F99-9C10-66BD63861F48Q38591052-C83CFE45-5EE9-4C7F-A319-81F3D28AB6BEQ38658328-B68EB71E-5001-45BE-85C9-7EC4CC1CBD6AQ38726509-8DC45973-6903-4222-B8B6-8C78DA5A0612Q38863770-FF6FDDCA-8B64-4236-8B8F-03F558D0138BQ38939643-A3C21987-59DF-41DA-85F4-D5E335BEDD90Q38957278-BBA04153-2721-4D41-8495-12E509D7FCE4Q38997041-6F0F482D-D116-4E0F-89FB-9241FF0D5E37Q39005508-43C09DC1-AF7C-4A4B-A5B0-C0D08AAD76B8Q39146671-ADBF5267-06A4-4C72-92BD-E22DAE0DFC65Q40187345-9BD9A703-F019-43D1-B89D-92E80745B942Q40366614-A820DD9B-FFE2-4FD3-AAB1-05549FE26A90Q40396244-8D2F9B3C-9363-4084-AB96-28086048B387
P2860
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@ast
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@en
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@nl
type
label
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@ast
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@en
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@nl
prefLabel
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@ast
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@en
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@nl
P1433
P1476
HHV-8-negative, idiopathic mul ...... gy, pathogenesis, and therapy.
@en
P2093
Christopher S Nabel
David C Fajgenbaum
P304
P356
10.1182/BLOOD-2013-12-545087
P407
P577
2014-03-12T00:00:00Z